{"meta":{"query_hash":"180dafccc7cc","filters":{"venue":"memo - Magazine of European Medical Oncology"},"cohort_total":4,"direct_labels_cover":0,"predictions_cover":4,"exported":4,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/180dafccc7cc","api":"https://metacan.xera.ac/api/v1/cohort?venue=memo+-+Magazine+of+European+Medical+Oncology"},"results":[{"id":"W3140318702","doi":"10.1007/s12254-021-00692-7","title":"ESMO 2020 update: Pancreatic cancer","year":2021,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medizinische Universität Wien","keywords":"Medicine; Pancreatic cancer; Oncology; Randomized controlled trial; Durvalumab; Regimen; Internal medicine; Gemcitabine; Clinical trial; Chemotherapy; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.0303082763436609,"score_gpt":0.3652405864764982,"score_spread":0.3349323101328373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140318702","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002555009,0.70588464,0.0024649166,0.068901494,0.049542386,0.00025680842,0.03426662,0.002033595,0.1340945],"genre_scores_gemma":[0.010605446,0.6963509,0.006255402,0.054953914,0.053927243,0.00053590705,0.08583825,0.00063855626,0.0908944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991972,0.0001509914,0.00012025589,0.000059371665,0.000384569,0.00008755279],"domain_scores_gemma":[0.9970004,0.00058455573,0.0006057082,0.00007920153,0.0011467902,0.0005833467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020307223,0.00093145896,0.0013653147,0.0042446917,0.0003572464,0.0026846817,0.0013151052,0.0021528814,0.023853457],"category_scores_gemma":[0.005036658,0.00037015416,0.0007381183,0.0036170753,0.00030538708,0.0017966451,0.0019048171,0.0025866465,0.024271647],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010256627,0.00002060293,0.00024443812,0.0011281866,0.000029396211,0.000056884022,0.000010676129,0.00012099653,0.0001509985,0.0005017233,0.7862351,0.21139838],"study_design_scores_gemma":[0.000021062773,0.000031828295,0.00047396103,0.0007585249,0.00003056344,0.00015983505,0.0000065956706,0.00003405883,0.00005976753,0.00019055062,0.9982279,0.0000054105644],"about_ca_topic_score_codex":0.0021235764,"about_ca_topic_score_gemma":0.005572366,"teacher_disagreement_score":0.023853457,"about_ca_system_score_codex":0.0014692289,"about_ca_system_score_gemma":0.001936268,"threshold_uncertainty_score":0.079797745},"labels":[],"label_agreement":null},{"id":"W4390405183","doi":"10.1007/s12254-023-00945-7","title":"Metastasis-directed therapy: new standard or too early to change paradigm?","year":2023,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Medizinische Universität Wien","keywords":"Medicine; Clinical trial; Tolerability; Context (archaeology); Prostate cancer; Disease; Intensive care medicine; Metastasis; Oncology; Internal medicine; Cancer; Adverse effect","score_opus":0.12546084868647786,"score_gpt":0.398598524580373,"score_spread":0.27313767589389515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390405183","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006261061,0.90626305,0.0020388602,0.08263033,0.0058301985,0.000036006313,0.00005363657,0.000038339564,0.0024834648],"genre_scores_gemma":[0.011447437,0.9134958,0.004362167,0.056591343,0.012127643,0.00013685744,0.00010342597,0.000045697456,0.0016895375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99471754,0.002436291,0.0007854523,0.00066404516,0.001159875,0.00023686451],"domain_scores_gemma":[0.985319,0.0093666855,0.0010801778,0.00054987235,0.003083847,0.00060038985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014225956,0.00065201876,0.0029053946,0.0012439259,0.0005827162,0.0044095144,0.0023024366,0.002961436,0.0034285253],"category_scores_gemma":[0.014462581,0.00029389802,0.0012100714,0.001121559,0.0036797847,0.008971931,0.0016830468,0.008971157,0.0019383875],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006967144,0.00019367771,0.00089198194,0.03560402,0.0005076602,0.0004079408,0.0005471078,0.0006252265,0.0017012955,0.0600392,0.08791138,0.8108738],"study_design_scores_gemma":[0.00021988021,0.00069758133,0.0009388559,0.027436461,0.00046798037,0.0011339277,0.0007892542,0.00040642518,0.00057769066,0.061295103,0.9059601,0.00007683753],"about_ca_topic_score_codex":0.0009653944,"about_ca_topic_score_gemma":0.0023708618,"teacher_disagreement_score":0.014225956,"about_ca_system_score_codex":0.0020835814,"about_ca_system_score_gemma":0.0055278908,"threshold_uncertainty_score":0.07523495},"labels":[],"label_agreement":null},{"id":"W4409502283","doi":"10.1007/s12254-025-01027-6","title":"EffiXane—Non-interventional study on safety and effectiveness of nab-paclitaxel (Abraxane®) + gemcitabine as first-line treatment of metastatic PDAC in a daily routine setting","year":2025,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Gemcitabine; Paclitaxel; Nab-paclitaxel; Medicine; Oncology; Deoxycytidine; First line; Pharmacology; Internal medicine; Chemotherapy","score_opus":0.0188733947914519,"score_gpt":0.3504243538497163,"score_spread":0.3315509590582644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409502283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956636,0.0015630699,0.00021598738,0.00011530384,0.00007457252,0.00046391334,0.0003571722,0.000034464378,0.0015120549],"genre_scores_gemma":[0.9912951,0.0016413581,0.0009560203,0.0005727573,0.00038090887,0.00046323088,0.0014319314,0.000024565396,0.0032342041],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9991505,0.00045098606,0.000055686185,0.00015859403,0.00007846154,0.00010568258],"domain_scores_gemma":[0.9990388,0.00031336813,0.00015933395,0.0001310768,0.000049007427,0.00030845508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014260922,0.00080607407,0.0014189531,0.000608768,0.00030426471,0.0008777806,0.0006393885,0.0009274959,0.004228822],"category_scores_gemma":[0.0011858083,0.00038031046,0.001595508,0.00030477656,0.0008798502,0.0010902694,0.00039093915,0.0026629523,0.0007561399],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8897662,0.04313328,0.0037169438,0.00024005499,0.0009499803,0.00009619362,0.000074759155,0.00038041847,0.008850978,0.00015552166,0.0005726735,0.05206305],"study_design_scores_gemma":[0.31079358,0.6669068,0.015315549,0.00003332732,0.00093345717,0.0001841088,0.000043029744,0.00062365877,0.0027554878,0.00018567119,0.0021906141,0.00003478108],"about_ca_topic_score_codex":0.0005611513,"about_ca_topic_score_gemma":0.0008954915,"teacher_disagreement_score":0.004228822,"about_ca_system_score_codex":0.0005959191,"about_ca_system_score_gemma":0.0008150149,"threshold_uncertainty_score":0.014146864},"labels":[],"label_agreement":null},{"id":"W4416771546","doi":"10.1007/s12254-025-01087-8","title":"EGFR-mutated advanced non-small cell lung cancer: new era of systemic therapy towards new standards of care","year":2025,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CARE Canada","funders":"","keywords":"Osimertinib; Clinical trial; Lung cancer; Chemotherapy; Standard of care; Systemic therapy","score_opus":0.009708134768383999,"score_gpt":0.3524578201357958,"score_spread":0.3427496853674118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416771546","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007177285,0.9861341,0.0016781336,0.007154739,0.0014231693,0.000016229049,0.000030291187,0.000038494894,0.002807116],"genre_scores_gemma":[0.0047013033,0.9856128,0.0017667226,0.0047229077,0.0020874175,0.000035535624,0.00008397957,0.000012689239,0.0009767057],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907506,0.00031507201,0.00012634405,0.000103390485,0.00031665107,0.00006335347],"domain_scores_gemma":[0.99925536,0.00034471837,0.00009465171,0.000026578417,0.00020931498,0.00006929789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014429105,0.00046239616,0.0010692185,0.00065333466,0.0002790095,0.0014063242,0.0006861881,0.00084873074,0.00186187],"category_scores_gemma":[0.0014456573,0.000121793295,0.00059476955,0.0007113388,0.00063600845,0.0020956036,0.0008468654,0.0023174875,0.00068486674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009747989,0.00005690748,0.00041079725,0.010279216,0.000118149626,0.0003423588,0.00018952307,0.0005097382,0.0022603194,0.011582335,0.06661944,0.9075337],"study_design_scores_gemma":[0.000025717203,0.00016619016,0.0005287495,0.003439059,0.000084206134,0.0010249191,0.0000954876,0.0001900621,0.00029492384,0.003849964,0.9902852,0.000015535297],"about_ca_topic_score_codex":0.000532941,"about_ca_topic_score_gemma":0.0014487471,"teacher_disagreement_score":0.00186187,"about_ca_system_score_codex":0.000947866,"about_ca_system_score_gemma":0.0020017123,"threshold_uncertainty_score":0.0076309443},"labels":[],"label_agreement":null}]}